All News

Found 3,307 articles

• Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors

  2/3/2023

  Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its ARM vaccine manufacturing

• Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results

  2/2/2023

  Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.

• ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder

  2/2/2023

  ADC Therapeutics SA today announced the pricing of an underwritten offering of 12,000,000 common shares of the Company currently owned by A.T. Holdings II Sàrl (the “Selling Shareholder”), an affiliate of Auven Therapeutics Holdings L.P., at a price of $5.00 per share.

• Mersana Therapeutics to Present at Upcoming Investor Conferences - February 02, 2023

  2/2/2023

  Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at the following upcoming investor conferences:

• Defence Therapeutics and CQDM Fund the Development of a New Cancer Vaccine Platform

  2/2/2023

  In celebration of World Cancer Day, Defence Therapeutics and CQDM are proud to announce the launch of a collaborative research project between Université de Montréal (UdeM), the Lady Davis Institute of the Jewish General Hospital and Defence Therapeutics, a Quebec-based biotechnology company specialized in the development of next-generation vaccines.

• enGene Appoints Alex Nichols, PhD as President and Chief Operating Officer

  2/2/2023

  enGene, Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced that Alex Nichols, PhD, has joined the company as President and Chief Operating Officer.

• Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer

  2/1/2023

  Mersana Therapeutics, Inc. today announced that patient dosing is underway in the expansion portion of its UPGRADE-A clinical trial of UpRi in combination with carboplatin in platinum-sensitive ovarian cancer.

• Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program

  2/1/2023

  Cidara Therapeutics, Inc. and WuXi XDC announced an expansion of their existing collaboration under which WuXi XDC will provide investigational new drug -enabling chemistry, manufacturing and controls development services for Cidara’s CD73 oncology DFC program.

• ADC Therapeutics to Participate in February Investor Conferences

  2/1/2023

  ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in February.

• Defence's Lung Cancer GLP tox Study on Its Intranasal AccuTOX(TM) Formulation Advances

  1/31/2023

  Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its GLP studies on a new intranasal AccuTOXTM formulation.

• 

  Amgen Downsizes by 300 Amid Industry Constriction

  1/30/2023

  Amgen is implementing organizational changes including laying off approximately 300 team members, confirmed Monday.

• TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer

  1/30/2023

  Daiichi Sankyo (TSE: 4568) today announced that the first patient has been dosed in the global, randomized TROPION-Lung07 phase 3 trial evaluating datopotamab deruxtecan.

• AmMax Bio Announces First Patients Dosed in Phase 2b Study of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

  1/30/2023

  AmMax Bio, Inc. (“AmMax”) today announced that the first patients have been dosed in the Company’s Phase 2b study evaluating AMB-05X for the treatment of tenosynovial giant cell tumor (TGCT).

• CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

  1/26/2023

  CytomX Therapeutics, Inc. today announced that it achieved a clinical candidate milestone under its TCB agreement with Astellas.

• Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors

  1/25/2023

  Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the initiation of patient dosing in its Phase 1 clinical trial of XMT-2056, the company’s lead Immunosynthen product candidate.

• Zymeworks Announces Participation in Upcoming Investor Conferences - January 25, 2023

  1/25/2023

  Zymeworks Inc. today announced that management will participate in the following upcoming investor conferences.

• Defence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated

  1/24/2023

  Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation of its ARM vaccine candidate in a melanoma model with a cure rate of 60%.

• RETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023

  1/23/2023

  Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies,

• DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma with HER2 Overexpression

  1/20/2023

  Duality Biologics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to DB-1303 for the treatment of patients with advanced, recurrent or metastatic endometrial carcinoma with HER2 overexpression who have progressed on or after standard systemic treatment.

• Defence To Present at The 9th Annual Immuno-Oncology 360 Summit in New-York February 7-10, 2023

  1/20/2023

  Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies,